Related Experiment Video
Updated: May 5, 2026
08:19
Patterning via Optical Saturable Transitions - Fabrication and Characterization
Published on: December 11, 2014
6.0K
Formulation patents and dermatology and obviousness.
Dan-Feng Mei1, Josephine Liu, Michael A Davitz
1Fordham University School of Law, 140 West 62nd Street, New York, NY 10023, USA. mad@avhlaw.com.
Pharmaceutics
|December 7, 2013
Summary
Formulation patents for dermatologic products face obviousness challenges. Courts consider prior art, even implicit features, but unexpected results or prior art teaching away can overcome these challenges.
Area of Science:
- Intellectual Property Law
- Pharmaceutical Sciences
- Dermatology
Background:
- Formulation patents are crucial for dermatologic products.
- These patents are susceptible to obviousness challenges based on prior art.
- Obviousness is a key legal defense in patent law.
Purpose of the Study:
- To examine recent court cases on obviousness and formulation patents.
- To understand how courts assess obviousness in the context of dermatologic formulations.
- To identify strategies for overcoming obviousness challenges.
Main Methods:
- Review and analysis of recent court rulings concerning formulation patents.
- Examination of legal arguments related to obviousness and prior art.
- Case study analysis of successful and unsuccessful patent challenges.
Main Results:
- Courts may find patent claims obvious if formulation features exist in prior art, even if not explicit.
- Unexpected results or properties of a formulation can be grounds for overcoming obviousness.
- Prior art that explicitly discourages or teaches away from the claimed invention can help patentees.
Conclusions:
- The legal landscape for dermatologic formulation patents is complex.
- Patentees must demonstrate novelty and non-obviousness, considering both explicit and implicit prior art.
- Highlighting unexpected benefits or contrary prior art strengthens patent claims against obviousness attacks.
More Related Videos
Related Concept Videos
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
420
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
420
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
300
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
300
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
547
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
547
01:21Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
883
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
883
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
834
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
834